Profile of lebrikizumab and its potential in the treatment of asthma.

摘要: Interleukin (IL)-13 has been associated with multiple inflammatory features of asthma. It affects cellular lines in asthma and is a key mediator airway hyperreactivity remodeling. Periostin, an extracellular protein, used as surrogate marker IL-13 activity linked to remodeling by inducing subepithelial fibrosis. Lebrikizumab humanized monoclonal antibody that targets IL-13. Studies have demonstrated promising results lebrikizumab therapy regard pulmonary function exacerbation rates, especially on those patients markers T helper cell type 2-driven inflammation (ie, elevated immunoglobulin E levels, eosinophil counts, periostin levels). appears be safe therapy, but there are ongoing studies evaluating its efficacy safety profile. Other therapies target the receptor IL-4/IL-13 studied, future needed determine their role treatment